Enter assignee name

EPO Patents = 5

Trademarks = 3

Forward Citations = 114

Loading Chart...

3 inventors (with patents filed for the assignee):

John S Petersen (15 out of 40 patents)

James Shanahan (11 out of 11 patents)

Peter Cornelius (4 out of 8 patents)

19 patents: Sort by Forward Citations

1. 12419846 - Biomarkers of METAP2 inhibitors and applications thereof (2025-09-23),

2. 11612577 - Biomarkers of METAP2 inhibitors and applications thereof (2023-03-28),

3. 11304944 - MetAP2 inhibitors and methods of treating obesity (2022-04-19),

4. 11273142 - Treatment for tumors driven by metabolic dysfunction (2022-03-15),

5. 10722532 - Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof (2020-07-28),

6. 10646463 - Treatment for tumors driven by metabolic dysfunction (2020-05-12),

7. 10588904 - METAP2 inhibitors and methods of treating obesity (2020-03-17),

8. 10287277 - Fumagillol derivatives and polymorphs thereof (2019-05-14),

9. 10159692 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2018-12-25),

10. 10010544 - METAP2 inhibitors and methods of treating obesity (2018-07-03),

11. 9969722 - Fumagillol derivatives and polymorphs thereof (2018-05-15),

12. 9895449 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2018-02-20),

13. 9757373 - MetAP2 inhibitors and methods of treating obesity (2017-09-12),

14. 9750737 - METAP2 inhibitors and methods of treating obesity (2017-09-05),

15. 9730955 - Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof (2017-08-15),

Syndevrx, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative therapeutic solutions. The organization focuses on advancing drug discovery and development processes, particularly in the fields of precision medicine and targeted therapies. By leveraging cutting-edge research and technology, Syndevrx aims to address unmet medical needs and improve patient outcomes through its specialized expertise in molecular biology and pharmacology.

Profile summary based on public USPTO records.